Through these functions, Cerviray AI was recognized for its excellence by measuring 98% of sensitivity and 91% of specificity in AI algorithm performance in clinical reports for approval by the Ministry of Food and Drug Safety. Jeong Jae Hoon, CEO of AIDOT, said, “When the commercialization of the product started in Korea, I heard that a woman in her 20s was screened with Cerviray AI and was diagnosed as early cancer and was able to start treatment right away. It was very meaningful that we could contribute to the patient’s life as she could be directly connected to treatment. Cerviray AI is currently being commercialized in various countries such as Indonesia, Mongolia, Uzbekistan, the Philippines, and Vietnam. In particular, AIDOT recently participated in the Indonesian Society of Gynecological Oncology through Cerviray AI, won the Director’s Award of Gangwon Techno Park, and was able to achieve the results of registration with the Vietnamese Ministry of Health and FDA approval. In addition to Cerviray AI, AIDOT has developed SONO dot AI, an AI carotid artery ultrasound stroke screening system, NAO dot AI, which predicts cerebral aneurysm rupture based on 3D angiography, and GIGA dot AI, which diagnoses gastrointestinal/colonoscopy in real time. Commercialization of BIO dot AI, a diagnostic solution for alcoholic liver disease, is also planned.